Abstract
Objective s To analysis the expression difference of eIF4E in bone marrow between the acute myeloid leukemia(AML)and the non-tumor patient, before and after induction therapy, and the different subtypes of AML, and to explore the relation between eIF4E and other molecular biology abnormalities in AML. Methods The bone marrow specimens of newly diagnosed AML and non-tumor control patients were collected. The expression level of eIF4E was detected by RT-PCR. Results The positive rate of eIF4E was 65.2 %(101/155)in AML. eIF4E turned to negative in 12 patients(17.6 %)who got complete remission after induction therapy. eIF4E was negatively expressed in bone marrow of the non-tumor control patients. The positive rates of eIF4E were 75.0 %(15/20)and 80.8 %(21/26)in M4 and M5 type AML, respectively, and was 59.6 %(65/109)in other subtype AML(P > 0.05). FLT3/ITD gene mutation was found in 26 cases of newly diagnosed AML. The eIF4E expression and FLT3-ITD gene mutation were independent each other(P> 0.05). Conclusions eIF4E is positive in most of the newly diagnosed AML and turns to negative in part of AML achieving complete remission. The expression of eIF4E is no difference among different subtype of AMLs. eIF4E and FLT3-ITD gene mutation are independent each other. Key words: eIF4E gene; Leukemia, myeloid, acute; PCR; FLT3-ITD
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
